A Toronto-based biotech company is studying a psychedelic drug based on DMT as a treatment for Alzheimer’s disease with a Phase ll clinical trial in Argentina.
A Toronto-based biotech company is studying a psychedelic drug based on DMT as a treatment for Alzheimer’s disease with a Phase ll clinical trial in Argentina.